Gerald V Doyle
Overview
Explore the profile of Gerald V Doyle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
6313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paoletti C, Miao J, Dolce E, Darga E, Repollet M, Doyle G, et al.
Clin Cancer Res
. 2019 Jul;
25(20):6089-6097.
PMID: 31358544
Purpose: Metastasis requires malignant cell circulation from the primary to a distant tissue. Elevated levels of circulating tumor cells (CTC) portend a poor prognosis in breast and other cancers. Recent...
2.
Smerage J, Barlow W, Hortobagyi G, Winer E, Leyland-Jones B, Srkalovic G, et al.
J Clin Oncol
. 2014 Jun;
32(31):3483-9.
PMID: 24888818
Purpose: Increased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized trial of...
3.
Smerage J, Budd G, Doyle G, Brown M, Paoletti C, Muniz M, et al.
Mol Oncol
. 2013 Mar;
7(3):680-92.
PMID: 23538216
Background: Enumeration of circulating tumor cells (CTC) from whole blood permits monitoring of patients with breast carcinoma. Analysis of apoptosis & Bcl-2 expression in CTC might add additional prognostic and...
4.
Miller M, Doyle G, Terstappen L
J Oncol
. 2009 Dec;
2010:617421.
PMID: 20016752
The increasing number of treatment options for patients with metastatic carcinomas has created a concomitant need for new methods to monitor their use. Ideally, these modalities would be noninvasive, be...
5.
Connelly M, Wang Y, Doyle G, Terstappen L, McCormack R
J Natl Cancer Inst
. 2009 Jun;
101(12):895.
PMID: 19509360
No abstract available.
6.
De Giorgi U, Valero V, Rohren E, Dawood S, Ueno N, Miller M, et al.
J Clin Oncol
. 2009 May;
27(20):3303-11.
PMID: 19451443
Purpose: Circulating tumor cells (CTCs) and [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) are two new promising tools for therapeutic monitoring. In this study, we compared the prognostic value...
7.
de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H, et al.
Clin Cancer Res
. 2008 Oct;
14(19):6302-9.
PMID: 18829513
Purpose: A method for enumerating circulating tumor cells (CTC) has received regulatory clearance. The primary objective of this prospective study was to establish the relationship between posttreatment CTC count and...
8.
Eliane J, Repollet M, Luker K, Brown M, Rae J, Dontu G, et al.
Cancer Res
. 2008 Jul;
68(14):5529-32.
PMID: 18632603
Circulating tumor cells (CTC) are emerging as a powerful prognostic and predictive biomarker in several types of cancer, including breast, colon, and prostate. Studies of CTC in metastasis and further...
9.
Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N, et al.
J Clin Oncol
. 2008 Jul;
26(19):3213-21.
PMID: 18591556
Purpose: As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role could guide treatment. We tested the hypothesis that circulating tumor cells...
10.
Shaffer D, Leversha M, Danila D, Lin O, Gonzalez-Espinoza R, Gu B, et al.
Clin Cancer Res
. 2007 Apr;
13(7):2023-9.
PMID: 17404082
Purpose: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent...